Key takeaways
- A standard cholesterol panel usually does not include Lp(a), so you need a separate blood test to find out your level.
- Current U.S. guidance recommends that every adult have Lp(a) measured at least once, even if LDL cholesterol looks normal.
- An Lp(a) level of 125 nmol/L or 50 mg/dL and above is considered a cardiovascular risk-enhancing factor, but risk rises gradually rather than beginning at one exact cutoff.
- Lp(a) may be reported in nmol/L or mg/dL, and the two units should not be converted with a simple fixed formula.
- Because high Lp(a) often runs in families, an elevated result can also be a reason for parents, siblings, and children to consider testing.
Lipoprotein(a), usually abbreviated Lp(a) and pronounced “L-P-little-a,” is a blood marker that can reveal an inherited source of cardiovascular risk that a routine cholesterol panel does not normally measure. Unlike LDL cholesterol or triglycerides, Lp(a) levels are determined primarily by genetics and generally remain fairly stable throughout life.
That makes Lp(a) testing unusual: for many adults, one measurement can provide useful lifelong risk information. The 2026 ACC/AHA dyslipidemia guideline recommends that Lp(a) be measured at least once in adulthood, while people with a personal or family history of premature cardiovascular disease, familial hypercholesterolemia, or known elevated Lp(a) in the family have especially strong reasons to know their level.
The result is not a diagnosis and does not predict exactly what will happen to an individual. Instead, Lp(a) is a risk-enhancing factor that should be interpreted alongside LDL cholesterol, blood pressure, diabetes, smoking, family history, age, existing cardiovascular disease, and other parts of the overall risk picture.
What does an Lp(a) test actually measure?
Lp(a) is a type of lipoprotein: a particle that transports fats and cholesterol through the bloodstream.
Structurally, an Lp(a) particle resembles an LDL particle. It contains cholesterol and apolipoprotein B-100, or ApoB-100. What makes it different is an additional protein called apolipoprotein(a), or apo(a), attached to the ApoB-containing particle.
That apo(a) component is important because it helps distinguish Lp(a) biologically from ordinary LDL particles. Elevated Lp(a) is associated with atherosclerotic cardiovascular disease and calcific aortic valve disease independently of many traditional cardiovascular risk factors.
The blood test measures the concentration of these Lp(a) particles or their mass, depending on the laboratory method.
It does not simply measure LDL cholesterol under another name.
And although each Lp(a) particle contains ApoB, an ApoB test cannot tell you specifically how much Lp(a) you have. That distinction is why Lp(a) and ApoB can provide complementary information rather than functioning as interchangeable tests.
Why can high Lp(a) increase cardiovascular risk?
Elevated Lp(a) is now considered an established risk factor for atherosclerotic cardiovascular disease.
Lp(a) particles can enter the artery wall and participate in plaque development much like other ApoB-containing lipoproteins. Lp(a) also carries oxidized phospholipids and has additional biological characteristics associated with inflammation and calcification. These properties are among the reasons Lp(a) is also associated with calcific aortic valve disease, in addition to heart attack, stroke, and other manifestations of atherosclerotic disease.
Importantly, the association is not explained simply by someone also having high LDL cholesterol. Lp(a) can add risk even when LDL-C is relatively favorable. That is one reason a person can have an apparently reassuring conventional lipid panel while still having an inherited lipoprotein-related risk factor that has never been measured.
Lp(a), however, is only one component of cardiovascular risk. A high result does not mean a heart attack or stroke is inevitable, and a low result does not guarantee protection from cardiovascular disease.
Why is Lp(a) mostly a genetic marker?
Lp(a) concentration is largely controlled by variation in the LPA gene, which influences production of apolipoprotein(a).
As a result, Lp(a) tends to run strongly in families. Diet, exercise, and weight loss can substantially influence several conventional cardiovascular risk factors, but they usually have relatively little effect on the Lp(a) concentration itself.
This is not a reason to conclude that healthy habits are unimportant for someone with elevated Lp(a). Rather, it means lifestyle changes primarily help by improving other modifiable cardiovascular risk factors instead of substantially changing the inherited Lp(a) value.
The genetic influence also explains why testing once can be informative for many years.
Who should get an Lp(a) test?
The most important change in recent guidance is that Lp(a) testing is no longer viewed only as a specialized investigation for people who already appear to be at unusually high cardiovascular risk.
The 2026 ACC/AHA Guideline on the Management of Dyslipidemia recommends measuring Lp(a) at least once in adulthood to identify people whose cardiovascular risk may be higher than traditional measurements suggest.
The National Lipid Association reached a similar conclusion in its 2024 focused update, recommending at least one Lp(a) measurement in every adult for cardiovascular risk stratification.
Testing can be particularly informative for people with a personal or family history of premature cardiovascular disease. The American Heart Association defines premature disease in this context as occurring before age 55 in men or before age 65 in women. Testing is also especially relevant when a close relative is known to have high Lp(a), or when someone has familial hypercholesterolemia, an inherited condition characterized by very high LDL cholesterol.
In practical terms, you do not need to wait until cholesterol is abnormal or cardiovascular disease develops before asking about Lp(a).
Should family members be tested if your Lp(a) is high?
Often, yes.
Because Lp(a) is strongly inherited, discovering an elevated concentration in one person can provide useful information for the rest of the family.
The National Lipid Association supports cascade screening of first-degree relatives when elevated Lp(a) is identified. First-degree relatives include parents, siblings, and children.
The American Heart Association similarly advises that close relatives may benefit from testing when high Lp(a) is found in the family.
This does not mean every relative will have the same concentration. Lp(a) levels can vary substantially even among family members. The value of family screening is that it can identify people who would otherwise have no reason to suspect that their level is elevated.
Testing children may also be considered when elevated Lp(a), familial hypercholesterolemia, or premature cardiovascular disease occurs in the family. The timing and implications of pediatric testing are best discussed with a clinician familiar with pediatric lipid disorders rather than applying adult thresholds and treatment decisions automatically to children.
Is Lp(a) included in a regular cholesterol test?
Usually not.
A conventional lipid panel generally reports:
| Standard lipid measurement | What it broadly reflects |
|---|---|
| Total cholesterol | Cholesterol carried across several lipoprotein types |
| LDL-C | Cholesterol carried within LDL and related particles |
| HDL-C | Cholesterol carried within HDL particles |
| Triglycerides | A major circulating form of fat |
Lp(a) requires a separate laboratory measurement. Someone can therefore have had cholesterol testing for decades without ever having had Lp(a) checked.
The test itself is a standard blood draw. Preparation requirements can vary by laboratory and by whatever other tests are being collected at the same time. Some laboratories perform a stand-alone Lp(a) assay without special preparation, while combined lipid-testing protocols may specify fasting. The safest approach is to follow the instructions from the laboratory or healthcare professional ordering the test rather than assuming fasting is always necessary or never necessary.
What is considered a high Lp(a) result?
Lp(a) interpretation can initially look confusing because results may be reported in different units.
The 2024 National Lipid Association update uses the following categories as a practical framework:
| Lp(a) concentration | General interpretation |
|---|---|
| Below 75 nmol/L or below 30 mg/dL | Lower Lp(a)-attributable risk |
| 75 to under 125 nmol/L or 30 to under 50 mg/dL | Intermediate range |
| 125 nmol/L or higher or 50 mg/dL or higher | Higher Lp(a)-attributable risk |
These are useful clinical categories, but Lp(a) does not behave like an on/off switch. Cardiovascular risk increases progressively as Lp(a) rises. Someone with 124 nmol/L is not suddenly low risk merely because the result falls one unit below 125 nmol/L.
The National Lipid Association specifically emphasizes this continuum of risk, while the 2026 ACC/AHA guideline identifies 125 nmol/L or 50 mg/dL and above as a risk-enhancing level.
What do very high Lp(a) numbers mean?
Higher concentrations generally correspond to greater long-term cardiovascular risk, but the size of that risk has to be interpreted carefully.
The 2026 ACC/AHA guideline summarizes population data indicating that an Lp(a) concentration around 125 nmol/L or 50 mg/dL is associated with roughly a 1.4-fold increase in atherosclerotic cardiovascular disease risk compared with a low reference concentration. At approximately 250 nmol/L or 100 mg/dL, estimated risk is about twice as high.
Those numbers describe relative risk at a population level. They do not mean that everyone with 250 nmol/L has a 100% chance of developing cardiovascular disease, nor do they translate directly into an individual’s absolute risk.
For example, doubling a relatively low baseline risk and doubling an already high baseline risk lead to very different absolute probabilities.
That is why Lp(a) should be added to an overall cardiovascular assessment rather than interpreted as a stand-alone prediction.
Why are some results in nmol/L and others in mg/dL?
This is one of the most common sources of confusion about Lp(a).
mg/dL measures the mass of Lp(a) present in a given volume of blood.
nmol/L reflects the molar concentration and therefore more closely represents the number of Lp(a) particles.
For many ordinary laboratory substances, converting from one unit to another is straightforward. Lp(a) is different because apolipoprotein(a) comes in different molecular sizes. One person’s Lp(a) particles may therefore have a different average mass than another person’s.
For that reason, the National Lipid Association strongly recommends against using a fixed conversion factor between mg/dL and nmol/L.
You may see internet calculators suggesting that a particular mg/dL result always equals a particular nmol/L value. Such conversions can produce misleading precision.
Instead, interpret the result in the unit the laboratory actually measured.
The commonly paired values—such as 125 nmol/L and 50 mg/dL—are clinical reference points, not proof that one is an exact mathematical conversion of the other.
Does ancestry change how Lp(a) should be interpreted?
Average Lp(a) concentrations vary among population groups. For example, higher average levels have been reported among people of African ancestry, and elevated concentrations are also common in some South Asian populations.
However, this should not be interpreted to mean that an elevated value can simply be dismissed as “normal for my ethnicity.”
The 2024 National Lipid Association update states that its Lp(a) risk categories apply across racial and ethnic groups. In other words, population differences in typical concentration do not eliminate the cardiovascular significance of an elevated result.
An individual’s Lp(a) should therefore be considered alongside that person’s complete medical and family history rather than interpreted solely from ancestry.
Do Lp(a) levels ever change?
Yes, but usually much less than measurements such as triglycerides or LDL cholesterol.
Because genetics account for much of a person’s Lp(a) concentration, the value tends to remain relatively stable over time. The 2026 guideline therefore notes that repeat testing generally is not necessary for most people.
There are exceptions.
Lp(a) may change during pregnancy and around menopause. Kidney disease, liver disease, thyroid disorders, and some other health circumstances can also influence measured levels.
A clinician may therefore consider repeating a measurement when the initial result was obtained during a potentially influential medical or physiological state, when a borderline result would materially affect a decision, or when another clinical reason makes reassessment useful.
Routine yearly Lp(a) testing is quite different from annual LDL-C monitoring and is generally unnecessary for someone whose circumstances have not changed.
Can your Lp(a) be high even if your LDL cholesterol is normal?
Yes.
That is one of the main reasons the test exists.
Lp(a) contains an LDL-like component, but its concentration is largely independent of the LDL-C number shown on a routine lipid panel. A person can have favorable LDL cholesterol while having substantially elevated Lp(a).
This also means a healthy lifestyle and a normal conventional cholesterol panel cannot reliably tell you whether your Lp(a) is low.
The only way to know is to measure it.
The reverse is also true: a low Lp(a) result does not cancel out high LDL-C or other cardiovascular risk factors. Each measurement provides different information.
Does a high Lp(a) result mean you have heart disease?
No.
Lp(a) is a risk factor, not an imaging study showing plaque and not a diagnosis of coronary artery disease, stroke, or aortic stenosis.
A person with elevated Lp(a) may never experience a cardiovascular event. Conversely, someone with low Lp(a) can develop cardiovascular disease for many other reasons.
The result becomes more meaningful when considered with factors such as LDL-C, non-HDL-C, ApoB, blood pressure, diabetes, kidney disease, tobacco exposure, family history, age, and whether cardiovascular disease is already present.
For some people whose risk remains uncertain, clinicians may also use tests such as coronary artery calcium imaging to clarify whether atherosclerosis is already present.
What happens after a high Lp(a) result?
An elevated result does not automatically mean that a specific medication must be started solely to reduce Lp(a).
Instead, current guidelines emphasize recognizing the added risk and addressing the cardiovascular factors that can be modified. The 2026 ACC/AHA guideline states that elevated Lp(a) should prompt consideration of more intensive LDL-C lowering and management of other cardiovascular risk factors.
That distinction is important because lowering the laboratory number itself and lowering the person’s actual risk of heart attack or stroke are not necessarily the same question.
The practical implications—including LDL management, blood pressure, smoking, exercise, diet, diabetes, family screening, and when specialist input may be helpful—are covered separately in our guide to what you can do about high Lp(a).
Five useful questions to discuss with a healthcare professional
If you receive an Lp(a) result, the most productive discussion is usually broader than simply asking whether the number is “good” or “bad.”
Useful questions include whether the result meaningfully changes your estimated cardiovascular risk; whether your LDL-C, non-HDL-C, or ApoB should be managed differently because of it; whether other risk-assessment tools would add useful information; whether close relatives should be tested; and whether there is any reason to repeat your Lp(a) measurement in the future.
The answers can differ substantially between someone who is young with no other major risk factors and someone who already has coronary artery disease, diabetes, familial hypercholesterolemia, or several additional risk factors.
What your Lp(a) result really tells you
The most useful way to think about an Lp(a) test is as a one-time look at an important inherited component of cardiovascular risk.
For most adults, current guidance supports measuring it at least once. A result below 75 nmol/L or 30 mg/dL generally indicates relatively low Lp(a)-attributable risk, while results at or above 125 nmol/L or 50 mg/dL are considered risk-enhancing. The numbers between those ranges are not meaningless; risk exists on a continuum.
Most importantly, a high Lp(a) result should neither be ignored nor treated as a prediction of inevitable disease. Its real value comes from placing an inherited risk factor that was previously hidden into the context of the rest of your cardiovascular health.
References
- Blumenthal RS, Morris PB, et al. “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia.” Circulation, 2026.
- Koschinsky ML, Bajaj A, Boffa MB, et al. “A Focused Update to the 2019 NLA Scientific Statement on Use of Lipoprotein(a) in Clinical Practice.” Journal of Clinical Lipidology, 2024.
- American Heart Association. “Lipoprotein(a).” Patient and professional cardiovascular education resource, reviewed 2026.
- American Heart Association. “ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol.” Guideline summary and news release, 2026.